Decitabine

Anti-PD-1 Antibody Resistant

Chinese PLA General HospitalSmall moleculePhase 2Dormant

B

60/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 45/ 100
Competitive Position: 95/ 100

Competitive context

181 Active assets in the Anti-PD-1 Antibody Resistant cohort.

Asset / Sponsor	Phase	Rating
Catequentinib Nanfang Hospital, Southern Medical University	Phase 3	BB
Irinotecan M.D. Anderson Cancer Center	Phase 2	BB
Durvalumab OHSU Knight Cancer Institute	Phase 2	BB
Cediranib National Cancer Institute (NCI)	Phase 2	BB
Nivolumab CatalYm GmbH	Phase 2	BB

View all 50 →

Same molecule, other indications

Decitabine is also rated in:

disease related to hematopoietic stem cell transplantDormant

BBB

Indicative ·

72 / 100

acute myeloid leukemia with t(8;21)(q22;q22) translocationDormant

BB

Indicative ·

70 / 100

acute myeloid leukemiaDormant

BB

Indicative ·

70 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.